Weert, Netherlands

Remy E J N Litjens

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Acerta Pharma B.v.. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Remy E J N Litjens. Retrieved from https://idiyas.com/inventor/remy-e-j-n-litjens

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 21.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Remy E J N Litjens: Innovator in Pharmaceutical Processes

Introduction

Remy E J N Litjens is a notable inventor based in Weert, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in the development of processes for drug preparation. His work is characterized by a focus on improving manufacturing efficiency and scalability.

Latest Patents

Litjens holds a patent for the processes related to the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridin-2-yl)-benzamide. This patent outlines improved methods for large-scale production of this compound and its intermediates, which are crucial for pharmaceutical applications.

Career Highlights

He is currently associated with Acerta Pharma B.V., where he continues to innovate in the pharmaceutical sector. His expertise in chemical processes has positioned him as a valuable asset in the development of new therapeutic agents.

Collaborations

Litjens has worked alongside notable colleagues such as Paul Allen Bethel and Lai Chun Chan. Their collaborative efforts have contributed to advancements in their respective fields and have fostered a productive research environment.

Conclusion

Remy E J N Litjens exemplifies the spirit of innovation in the pharmaceutical industry through his patented processes and collaborative work. His contributions are paving the way for more efficient drug manufacturing techniques.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…